Weight loss injections vs tablets: which actually works better?

Step 1 — understand what each format is and what it is licensed for

Two GLP-1 receptor agonist medicines are licensed in the UK for weight management in adults: semaglutide, available as a weekly injection (Wegovy) or a daily tablet (Wegovy tablets, approved by the MHRA on 11 June 2026); and tirzepatide, available only as a weekly injection (Mounjaro). Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it activates two gut-hormone pathways rather than one, currently the only medicine of its kind licensed for weight loss in the UK. The NHS's patient information for tirzepatide and NICE's appraisal of both medicines set the clinical backdrop for this comparison.

One distinction worth stating plainly: Ozempic is also semaglutide, but it is licensed for type 2 diabetes, not weight management. Rybelsus is also oral semaglutide, but again, it is licensed for diabetes, not weight loss. If you have read about either in a weight-loss context, you are looking at an off-label use. The licensed weight-loss tablet is Wegovy in tablet form, not Rybelsus. Our treatment overview covers what is actually dispensed through a regulated UK pharmacy.

The injection and tablet formats share a mechanism (slowing gastric emptying and reducing appetite) but differ in how the medicine reaches the bloodstream, how it must be taken, and what the trial evidence shows, and if you are already wondering which format has the edge, our page on whether tablets or injections are better for weight loss sets out that question in full before you read on.

Step 2, look at what the clinical trials actually found

A question our prescribers hear most weeks is some version of: "if I hate needles, does the tablet work just as well?" The honest answer is: it depends on which injection you are comparing it to.

The weekly semaglutide injection (Wegovy 2.4mg) produced an average body-weight reduction of around 15% over 68 weeks in the STEP 1 trial, published in the New England Journal of Medicine. The oral semaglutide tablet (Wegovy 25mg) produced an average of around 13.6% over 64 weeks in the OASIS 4 phase-3 trial, or approximately 17% among participants who adhered fully to treatment. That 17% figure only applies to full adherents, so the like-for-like average is closer to 13–14%.

Tirzepatide at its highest dose (15mg injection) showed average reductions of around 20–21% over 72 weeks in SURMOUNT-1, and in the SURMOUNT-5 head-to-head trial it produced greater average loss than semaglutide 2.4mg, as NICE noted in TA1026. There is no head-to-head trial yet comparing tirzepatide directly with the oral semaglutide tablet, which is one reason it is worth reading about whether weight loss tablets are as good as injections before drawing firm conclusions from the numbers below.

Numbers from different trials are not directly comparable: participant populations, trial lengths and definitions of adherence all vary. They are useful as orientation, not as a shopping list.

Step 3, weigh the practical differences that matter to you

The tablet has two genuine advantages the trial data cannot fully capture. First, no needle. For people with needle anxiety, that is not a minor point. Second, no refrigeration. The Wegovy tablet stores at room temperature, which makes it simpler to travel with and easier to fit into a routine, first thing in the morning, before the kettle boils, with a small glass of plain water. You wait at least 30 minutes before eating, drinking anything else or taking other oral medicines. That discipline is the trade-off: the tablet's absorption depends on an empty stomach, and missing that window affects how much medicine reaches the bloodstream.

The injection requires a working fridge, site rotation (abdomen, thigh or upper arm), and a sharps disposal arrangement, see the NHS tirzepatide page for injection-site guidance. For people who are comfortable with the process, once-weekly is many people's preference over once-daily, and our page looking at whether injections or pills are better for weight loss explores that preference in more practical terms. The side-effect profile for both formats is dominated by gastrointestinal symptoms (nausea, constipation, diarrhoea, reflux) that tend to be most noticeable after starting or a dose increase. The tablet produced GI side effects in about 74% of participants in OASIS 4 versus 42% in the placebo group. Whether that rate differs meaningfully from the injection route in practice is something the prescriber discusses with you at the eligibility stage.

You can read more about how weight loss injections work or explore the tablet vs injection question in more detail if a specific aspect of this comparison is your main concern.

Step 4, let a prescriber match the format to your situation

Eligibility for the injection and the tablet differs slightly. The weekly semaglutide injection and the tirzepatide injection are both licensed from a BMI of 30 or above, or from 27 with at least one weight-related condition such as hypertension, high cholesterol or obstructive sleep apnoea. The Wegovy tablet shares the same BMI threshold. Lower thresholds apply for some ethnic backgrounds under UK guidance. BMI alone is never the whole picture: prescribers look at your medical history, any existing conditions, current medicines and your preferences before recommending a format.

Tirzepatide is not available on the NHS for most people yet, the rollout is phased and criteria are strict. Semaglutide via a specialist NHS weight management service is an option for some, but waiting times are commonly long. A regulated online pharmacy is the private alternative for people who meet the clinical criteria but cannot access or do not want to wait for NHS treatment. Our clinical team reviews every consultation personally before any prescription is issued.

If you are weighing up which route suits you, the pills vs injections page covers additional angles, and the weight loss treatment overview explains all the options available through nume. Which format is right for you is a clinical decision our prescribers make with you, not one any comparison table can settle on its own.